Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech IPO
Biotech
BioVie plans $20M IPO for spinout developing liver disease drug
BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved low blood pressure drug to market.
James Waldron
Mar 17, 2026 5:18am
Salspera plans $91M IPO to fund salmonella-based cancer therapy
Mar 11, 2026 6:45am
Behind Generate's 'feverish' race to raise $400M IPO
Feb 27, 2026 3:36am
Generate plans $425M IPO to bankroll phase 3 asthma trials
Feb 23, 2026 9:42am
Preclinical eye disease biotech sets sights on $17M NYSE IPO
Feb 18, 2026 8:55am
Cell therapy biotech could end Tokyo IPO drought with $92M offer
Feb 17, 2026 11:06am
